Opportunity Information: Apply for PAR 09 135
Apply for PAR 09 135
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Replication, Fine Mapping and Sequencing Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Mar 20, 2009 and posted on Mar 20, 2009.
- Applicants must submit their applications by Jun 29, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Small businesses Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Special district governments Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) released this R01 funding opportunity (PAR-09-135) to push genetic findings beyond the initial genome-wide association study (GWAS) signal and toward a clearer understanding of what variants and genes actually drive disease risk. The central aim is to fund follow-up human genetics work that strengthens and refines putative associations for conditions in NIAMS's mission area, including arthritis, musculoskeletal disorders, and skin diseases. In practical terms, the FOA is trying to move the field from "this region of the genome seems linked to the trait" to "these specific variants and genes are likely causal, and here is strong evidence across studies and populations."
The announcement specifically encourages three types of follow-up studies focused on human genomic regions already implicated by GWAS: replication, fine mapping, and sequencing. Replication means testing previously reported GWAS associations in additional samples to confirm that the relationship is real and not a statistical fluke or specific to a single cohort. Fine mapping refers to a denser, more targeted evaluation of variants in and around the GWAS-identified locus to pinpoint which variants best explain the association signal, often leveraging linkage disequilibrium patterns and improved coverage of the region. Sequencing follow-up is intended to identify potentially functional variants, including rare or low-frequency variants that standard GWAS chips may not capture, within the associated regions. All of these approaches are framed as steps toward identifying causal genes and genetic variants that influence complex, multifactorial NIAMS-relevant diseases.
A key boundary in this FOA is that the work must be conducted in existing cohorts that already have defined phenotypes. NIAMS is not offering support here for building new cohorts or starting from scratch. The announcement explicitly does not support recruitment of new human subjects, new collection of medical or phenotypic data, animal model studies, or the initial discovery phase of a GWAS. The funded work is meant to capitalize on already-characterized datasets and samples, using them to validate signals and dig deeper into the biology of associated loci rather than to generate first-pass discoveries.
The mechanism is the standard NIH Research Project Grant (R01), and the FOA also leaves room for certain revision applications. If an investigator already holds an active NIAMS R01 that supports a two-stage GWAS (for example, discovery plus an initial replication stage), NIAMS allows submission of a revision (formerly called a competing supplement) in response to this FOA to extend the project into additional replication, fine mapping, or sequencing. Those revision applications still need to follow the FOA's budget limits and the usual NIH formatting rules for revisions, meaning the scope has to be a logical extension of the parent award rather than a wholly new project.
Funding levels are relatively focused and short-term, reflecting the targeted nature of follow-up genetics work. NIAMS anticipated committing about $1.5 million in total costs per year in each of fiscal years 2010, 2011, and 2012, with an expectation of supporting roughly three to four new projects per year. Applicants could request up to $250,000 in direct costs per year for a project period of up to two years. As with most NIH opportunities, awards depend on available funds and the quality and competitiveness of submitted applications.
Eligibility is broad and includes many types of domestic and non-domestic institutions and organizations. Eligible applicants listed for this FOA include public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) entities), small businesses, for-profit organizations (other than small businesses), and various levels of government (state, county, city/township, special district), as well as public housing authorities/Indian housing authorities. The FOA also calls out additional eligible applicants such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, U.S. territories or possessions, and foreign organizations or other non-U.S. entities, among others.
Administratively, this opportunity was posted March 20, 2009, with a closing date of June 29, 2011 (and an archive date of July 30, 2011). The CFDA program number associated with the scientific area is 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). Overall, the announcement is best understood as a targeted NIAMS investment in the crucial middle step between GWAS discovery and biological mechanism: confirming signals in independent data, narrowing down the likely causal variants, and using sequencing to uncover functional or rare variation that can clarify which genes and pathways are truly involved.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is an NIH NIAMS R01 funding opportunity (PAR-09-135) focused on follow-up human genetics studies that move beyond an initial genome-wide association study (GWAS) signal toward identifying the specific variants and genes that drive disease risk.
What is the main goal of the FOA?
The central goal is to strengthen and refine putative GWAS associations for NIAMS-relevant conditions so that findings progress from "a genomic region is associated" to "specific variants and genes are likely causal," supported by strong evidence across studies and populations.
What diseases or research areas does NIAMS consider within scope?
The FOA targets conditions within the NIAMS mission area, including arthritis, musculoskeletal disorders, and skin diseases.
What types of studies does the FOA encourage?
The announcement specifically encourages three types of follow-up studies in human genomic regions already implicated by GWAS: replication studies, fine mapping, and sequencing.
What does "replication" mean in this FOA?
Replication means testing previously reported GWAS associations in additional samples to confirm the association is real and not a statistical fluke or limited to a single cohort.
What does "fine mapping" mean in this FOA?
Fine mapping is a denser, more targeted evaluation of variants in and around the GWAS-identified locus to pinpoint which variants best explain the association signal, often using linkage disequilibrium patterns and improved coverage of the region.
What does "sequencing follow-up" mean in this FOA?
Sequencing follow-up is intended to identify potentially functional variants, including rare or low-frequency variants that typical GWAS arrays may not capture, within the associated genomic regions.
Does the FOA support the initial discovery phase of a GWAS?
No. The FOA is focused on follow-up work after a GWAS signal has already been identified. It explicitly does not support the initial discovery phase of a GWAS.
Do applicants need to use existing cohorts?
Yes. A key boundary is that the work must be conducted in existing cohorts that already have defined phenotypes. The funded work is meant to capitalize on already-characterized datasets and samples.
Does the FOA fund recruitment of new human subjects?
No. The announcement explicitly does not support recruitment of new human subjects.
Does the FOA support new collection of medical or phenotypic data?
No. The FOA explicitly does not support new collection of medical or phenotypic data.
Are animal model studies allowed under this FOA?
No. The announcement explicitly does not support animal model studies.
What grant mechanism is used for this opportunity?
The mechanism is the NIH Research Project Grant (R01).
Are revision applications allowed?
Yes. The FOA leaves room for certain revision applications. If an investigator already has an active NIAMS R01 supporting a two-stage GWAS (such as discovery plus an initial replication stage), NIAMS allows submission of a revision in response to this FOA to extend into additional replication, fine mapping, or sequencing.
What are the rules for revision applications under this FOA?
Revision applications must follow the FOA's budget limits and the usual NIH formatting rules for revisions, and the scope must be a logical extension of the parent award rather than a wholly new project.
How much funding is available per award?
Applicants could request up to $250,000 in direct costs per year.
How long can the project period be?
The project period can be up to two years.
How much total funding did NIAMS anticipate committing?
NIAMS anticipated committing about $1.5 million in total costs per year in each of fiscal years 2010, 2011, and 2012.
How many awards did NIAMS expect to make each year?
NIAMS expected to support roughly three to four new projects per year.
Are awards guaranteed if an application is submitted?
No. As with most NIH opportunities, awards depend on available funds and the quality and competitiveness of submitted applications.
Who is eligible to apply?
Eligibility is broad and includes many types of domestic and non-domestic institutions and organizations, including public and private institutions of higher education; nonprofits (including 501(c)(3) and non-501(c)(3)); small businesses; for-profit organizations (other than small businesses); and various levels of government (state, county, city/township, special district), as well as public housing authorities/Indian housing authorities.
Does the FOA include specific categories of eligible institutions?
Yes. The FOA calls out additional eligible applicants such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, U.S. territories or possessions, and foreign organizations or other non-U.S. entities, among others.
Are foreign (non-U.S.) organizations eligible?
Yes. Foreign organizations or other non-U.S. entities are listed among eligible applicants.
What is the CFDA program number associated with this opportunity?
The CFDA program number associated with the scientific area is 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research).
When was this opportunity posted?
The opportunity was posted on March 20, 2009.
What was the closing date for applications?
The closing date was June 29, 2011.
When was the announcement archived?
The archive date was July 30, 2011.
What is the practical intent of this FOA for the field?
The FOA is intended to support the key middle step between GWAS discovery and biological mechanism by confirming signals in independent data, narrowing likely causal variants through fine mapping, and using sequencing to uncover functional or rare variation that helps clarify which genes and pathways are truly involved.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Clean Energy Application Centers
Previous opportunity: Recovery Act State Energy Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 09 135
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 09 135) also looked into and applied for these:
| Funding Opportunity |
|---|
| Statewide Family Network Grant Apply for SM 09 016 Funding Number: SM 09 016 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $60,000 |
| A Cooperative Agreement for Monitoring Youth Exposure to Alcohol Marketing Apply for CDC RFA DP09 906 Funding Number: CDC RFA DP09 906 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| 2009 Family Planning Research Cooperative Agreement Apply for PA FPR 09 001 Funding Number: PA FPR 09 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $400,000 |
| Communication and Technical Assistance Support for HIV/AIDS Prevention Programs Apply for CDC RFA PS09 921 Funding Number: CDC RFA PS09 921 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| Expansion and Strengthening of Clinic Based HIV Related Services in Haiti under the President s Emergency Plan for AIDS Relief Apply for CDC RFA PS09 917 Funding Number: CDC RFA PS09 917 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $425,000 |
| A Door to Door Approach to Strengthen Community Based Interventions for HIV/AIDS Prevention, Care and Treatment in the Republic of Namibia under the President s Emergency Plan for AIDS Relief Apply for CDC RFA PS09 954 Funding Number: CDC RFA PS09 954 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,990,191 |
| Technical Assistance Center for Mental Health Promotion and Youth Violence Prevention Apply for SM 09 010 Funding Number: SM 09 010 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $500,000 |
| Supplements to State Mental Health Data Infrastructure Grants for Quality Improvement Apply for SM 09 018 Funding Number: SM 09 018 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $12,500 |
| Cooperative Agreements for Linking Actions for Unmet Needs in Children s Health Apply for SM 09 009 Funding Number: SM 09 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $850,000 |
| Expanding the Overseas Health Assessment and Surveillance of U.S. Bound Refugees Apply for CDC RFA CI09 902 Funding Number: CDC RFA CI09 902 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| 2009 Announcement of Availability of Funds for Embryo Donation and/or Adoption Public Awareness Campaign Cooperative Agreement Projects. Apply for PA EAA 09 001 Funding Number: PA EAA 09 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $500,000 |
| National Organization for Nutrition Programs Apply for CDC RFA DP09 910 Funding Number: CDC RFA DP09 910 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $850,000 |
| National Child Traumatic Stress Initiative Category II Treatment and Services Adaptation Centers Apply for SM 09 005 Funding Number: SM 09 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $600,000 |
| National Child Traumatic Stress Initiative Community Treatment and Services Centers Grants Apply for SM 09 017 Funding Number: SM 09 017 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $400,000 |
| Promoting Careers in Aging and Health Disparities Research (K01) Apply for PAR 09 136 Funding Number: PAR 09 136 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Training and Technical Assistance Center for Primary and Behavioral Health Care Integration Apply for SM 09 012 Funding Number: SM 09 012 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $900,000 |
| Developing Sustainable Influenza Surveillance Networks and Response to Avian and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP09 906 Funding Number: CDC RFA IP09 906 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| National Child Traumatic Stress Initiative National Center for Child Traumatic Stress Apply for SM 09 006 Funding Number: SM 09 006 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $5,000,000 |
| Cooperative Agreements for State/Community Partnerships to Integrate Services and Supports for Youth and Young Adults 16 25 with Serious Mental Health Conditions And Their Families Apply for SM 09 008 Funding Number: SM 09 008 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $480,000 |
| SOCIAL SERVICES FOR VULNERABLE POPULATIONS (SSVP) Apply for USAID RWANDA 696 09 004 DRAFT RFA Funding Number: USAID RWANDA 696 09 004 DRAFT RFA Agency: Rwanda USAID Kigali Category: Health Funding Amount: $60,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 09 135", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.